期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 195, 期 2, 页码 162-173出版社
WILEY
DOI: 10.1111/bjh.17419
关键词
Mantle cell lymphoma; pathogenesis; genetics; prognostication; therapy
类别
Mantle cell lymphoma (MCL) exhibits heterogeneous behavior, with treatment options needing to be tailored based on individual risk profiles for optimal outcomes. Recent advances in understanding the molecular background of MCL have led to innovative therapies and improved treatment recommendations for primary and relapsed/refractory MCL.
Mantle cell lymphoma (MCL) is clinically characterised by its heterogenous behaviour with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL with a very limited prognosis. A better understanding of the complex biology of MCL has already led to the approval of several innovative agents, expanding the landscape of MCL therapies and improving therapeutic options especially for refractory/relapsed (R/R) disease. Nevertheless, to further optimise MCL treatment, early identification of individual risk profile and risk-adapted, patient-tailored choice of therapeutic strategy needs to be prospectively incorporated into clinical patient management. The present review highlights recent advances in deciphering the molecular background of MCL, the definition of prognostically relevant factors and the identification of potential druggable targets and summarises current treatment recommendations for primary and R/R MCL including novel targeted therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据